Lim Do Hyoung, Lee Jeeyun, Lee Hong Ghi, Park Byeong-Bae, Peck Kyong Ran, Oh Won Sup, Ji Sang Hoon, Lee Se-Hoon, Park Joon Oh, Kim Kihyun, Kim Won Seog, Jung Chul Won, Park Young Suk, Im Young-Hyuck, Kang Won Ki, Park Keunchil
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea.
J Korean Med Sci. 2006 Jun;21(3):406-11. doi: 10.3346/jkms.2006.21.3.406.
Despite advanced effective prophylaxes, pulmonary complications still occur in a high proportion of all hematopoietic stem cell recipients, accounting for considerable morbidity and mortality. The aim of our study was to describe the causes, incidences and mortality rates secondary to pulmonary complications and risk factors of such complications following hematopoietic stem cell transplantation (HSCT). We reviewed the medical records of 287 patients who underwent either autologous or allogeneic HSCT for hematologic disorders from February 1996 to October 2003 at Samsung Medical Center (134 autografts, 153 allografts). The timing of pulmonary complications was divided into pre-engraftment, early and late period. The spectrum of pulmonary complications included infectious and non-infectious conditions. 73 of the 287 patients (25.4%) developed pulmonary complications. Among these patients, 40 (54.8%) and 29 (39.7%) had infectious and non-infectious conditions, respectively. The overall mortality rate from pulmonary complications was 28.8%. Allogeneic transplant, grade II-IV acute graft-versus-host disease (GVHD) and extensive chronic GVHD were the risk factors with statistical significance for pulmonary complications after HSCT. The mortality rates from pulmonary complications following HSCT were high, especially those of viral and fungal pneumonia, diffuse alveolar hemorrhage and idiopathic pneumonia syndrome.
尽管有先进有效的预防措施,但肺部并发症仍在很大比例的造血干细胞接受者中发生,导致相当高的发病率和死亡率。我们研究的目的是描述造血干细胞移植(HSCT)后肺部并发症的原因、发生率、继发死亡率以及此类并发症的危险因素。我们回顾了1996年2月至2003年10月在三星医疗中心接受自体或异基因HSCT治疗血液系统疾病的287例患者的病历(134例自体移植,153例异体移植)。肺部并发症的发生时间分为植入前、早期和晚期。肺部并发症的范围包括感染性和非感染性情况。287例患者中有73例(25.4%)发生了肺部并发症。在这些患者中,分别有40例(54.8%)和29例(39.7%)患有感染性和非感染性疾病。肺部并发症的总体死亡率为28.8%。异基因移植、II-IV级急性移植物抗宿主病(GVHD)和广泛的慢性GVHD是HSCT后肺部并发症具有统计学意义的危险因素。HSCT后肺部并发症的死亡率很高,尤其是病毒和真菌性肺炎、弥漫性肺泡出血和特发性肺炎综合征的死亡率。